FindTrial
Sign In

Application of acute isocompatible hemodilution combined with recovery autotransfusion in orthopedic surgery

Application of acute isocompatible hemodilution combined with recovery autotransfusion in orthopedic surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093526
Enrollment
Unknown
Registered
2024-12-06
Start date
2024-12-15
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Massive intraoperative blood loss

Interventions

Acute isocompatible hemodilution (ANH) combined with recovery autologous transfusion (SAT) group:Acute isocompatible hemodilution combined with recovery autologous transfusion
Recovery autologous transfusion (SAT) group:recovery autologous transfusion

Sponsors

Shaanxi 215 Hospital of nuclear industry
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.general anesthesia; 2.ASA grade I~ III; 3.age 18~ 75 years; 4.Hb = 110g/L; 5.body weight >= 50kg; 6.cardiac function grade I~ II; 7.estimated intraoperative bleeding >= 400ml; 8.class I surgical incision orthopedic surgery.

Exclusion criteria

Exclusion criteria: 1.Exclusion criteria: coagulation dysfunction or platelet < 100 × 10^9/L; 2.patients with severe cardiac, pulmonary, hepatic and renal dysfunction; 3.patients with severe hypertension; 4.patients with sepsis.

Design outcomes

Primary

MeasureTime frame
Allogeneic blood transfusion volume;—

Secondary

MeasureTime frame
Hb;Hct;Lac;Hb;urine volume;The amount of autotransfusion;amount of bleeding;Total transfusion cost;PT;APTT;PLT;Hct;PPV;Utilization rate of vasoactive drugs;—

Countries

China

Contacts

Public ContactLiuqin Jiang

Shaanxi 215 Hospital of nuclear industry

jlq215hp@163.com+86 29 32088348

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026